Jan. 27th, 2014
Wako Life Sciences, Inc. receives the Northern California Section 2013 AACC Outstanding Contribution to Clinical Chemistry in Science and Technology award for the development of the μTASWako® i30 Immunoanalyzer
Mountain View CA, January 27th, 2013Dr. Shinji Satomura, President, and Dr. Henry Wada, CSO of Wako Life Sciences, Inc., received an award from the Northern California Section of AACC for the scientific and technology contribution to clinical chemistry achieved by the development of the μTASWako i30 Immunoanalyzer.
Jul. 29th, 2013
Wako Diagnostics granted Medical Device Licences from Health Canada for the μTASWako® i30 Immunoanalyzer, and AFP-L3 and DCP Assays for Liver Cancer Risk Assessment
Mountain View CA, July 29th, 2013Wako Diagnostics, a division of Wako Life Sciences, Inc., was issued three Class III Medical Device Licences by Health Canada on April 23, 2013 to market the μTASWako i30 instrument with serum biomarkers lectin-reactive alpha-fetoprotein (AFP-L3) and des-gamma-carboxy prothrombin (DCP) tests for clinical use in Canada. The AFP-L3 and DCP tests are intended for in vitro diagnostic use as an aid in the risk assessment of patients with chronic liver disease for development of hepatocellular carcinoma (HCC) in conjunction with other laboratory findings, imaging studies and clinical assessment.
Clinical Diagnostic Reagents:
HCC Biomarkers and
Wako is a comprehensive manufacturer of Clinical Diagnostic reagents that are of the highest quality and good value to performance. Our products are the result of nearly 90 years of dedication to the field of in vitro diagnostics.
For Hepatocellular Carcinoma (HCC) Risk Assessment
Adding the two biomarkers, AFP-L3 and DCP, to your current HCC surveillance practice can increase your chances of detecting early HCC. These tests are available now through major reference laboratories in the United States and Canada.